Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis
| Autor: | Jason M. Scovell, Christina K. Mai, Alexander W. Pastuszak, Adam B. Hollander, Tung-Chin Hsieh, Larry I. Lipshultz, William G. Johnson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Cabergoline Anorgasmia Urology Endocrinology Diabetes and Metabolism media_common.quotation_subject 030232 urology & nephrology lcsh:Medicine Dermatology Orgasm Dopamine agonist Serum prolactin 03 medical and health sciences Behavioral Neuroscience 0302 clinical medicine Endocrinology medicine Male Orgasmic Disorder media_common Original Research Gynecology 030219 obstetrics & reproductive medicine business.industry lcsh:R Treatment options lcsh:Other systems of medicine lcsh:RZ201-999 Psychiatry and Mental health Reproductive Medicine Orgasmic dysfunction Outcomes Assessment Male orgasmic disorder business medicine.drug |
| Zdroj: | Sexual Medicine, Vol 4, Iss 1, Pp e28-e33 (2016) Sexual Medicine |
| ISSN: | 2050-1161 |
| Popis: | Introduction Male orgasmic disorder is common, with few treatment options. Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction. Aims To determine whether cabergoline increases the potential for orgasm in men with orgasmic disorder. Methods A retrospective chart review of men treated in a single andrology clinic for delayed orgasm or anorgasmia in a pilot study using cabergoline 0.5 mg twice weekly was performed. Duration of treatment and response were noted. Medical records were examined for other factors including history of prostatectomy and concomitant androgen supplementation. Main Outcome Measures Subjective improvement in orgasmic function resulting from cabergoline treatment. Results Of 131 men treated with cabergoline for orgasmic disorder, 87 (66.4%) reported subjective improvement in orgasm and 44 (33.6%) reported no change in orgasm. Duration of therapy (P = .03) and concomitant testosterone therapy (P = .02) were associated with a significant positive response to cabergoline treatment. No differences were found between injectable and non-injectable testosterone formulations (P = .90), and neither age (P = .90) nor prior prostatectomy (P = .41) influenced the outcome of cabergoline treatment. Serum testosterone levels before (P = .26) and after (P = .81) treatment were not significantly different in responders vs non-responders. Conclusion Cabergoline is a potentially effective and easy-to-administer treatment for male orgasmic disorder, the efficacy of which appears to be independent of patient age or orgasmic disorder etiology. Prospective randomized trials are needed to determine the true role of cabergoline in the treatment of this disorder. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|